Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2024

04-08-2023 | Metastasis | Original Article

Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma

Authors: Chuimian Zeng, Hai Li, Weiwei Liang, Junxin Chen, Yilin Zhang, Hanrong Zhang, Haipeng Xiao, Yanbing Li, Hongyu Guan

Published in: Endocrine | Issue 1/2024

Login to get access

Abstract

Purpose

StAR Related Lipid Transfer Domain Containing 13 (STARD13) serves as a tumor suppressor and has been characterized in several types of malignancies. However, the role and the molecular mechanism of STARD13 in regulating the progression of papillary thyroid carcinoma (PTC) remain underexplored.

Methods

The gene expression and clinical information of thyroid cancer were downloaded using “TCGAbiolinks” R package. Quantitative PCR and immunohistochemical staining were conducted to detect the expression of STARD13 in clinical tumor and adjacent non-tumor samples. Wound-healing assay, Transwell assay and 3D spheroid invasion assay were performed to evaluate the migratory and invasive capacities of PTC cells. Cell proliferation ability was determined by CCK-8 assay, colony formation assay and 5-ethynyl-2’-deoxyuridine (EdU) incorporation assay. The alterations of indicated proteins were detected by Western blotting.

Results

In the present study, we found that STARD13 was significantly underexpressed in PTC, which was correlated with poor prognosis. Downregulation of STARD13 might be due to methylation of promoter region. Loss-and gain-of-function experiments demonstrated that STARD13 impeded migratory and invasive capacities of PTC cells in vitro and in vivo. In addition, we found that STARD13 regulated the morphology of PTC cells and inhibited epithelial-mesenchymal transition (EMT).

Conclusion

Our results suggest that STARD13 acts as a metastasis suppressor and might be a potential therapeutic target in PTC.
Appendix
Available only for authorised users
Literature
1.
H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021)PubMedCrossRef
2.
F. Basolo, E. Macerola, A.M. Poma, L. Torregrossa, The 5(th) edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma. Endocrine 80(3), 470–476 (2023)PubMedPubMedCentralCrossRef
3.
T. Yan, W. Qiu, J. Song, Y. Fan, Z. Yang, ARHGAP36 regulates proliferation and migration in papillary thyroid carcinoma cells. J. Mol. Endocrinol. 66(1), 1–10 (2021)PubMedCrossRef
4.
L. Torregrossa, D. Viola, E. Sensi, M. Giordano, Piaggi, C. Romei et al. Papillary thyroid carcinoma with rare exon 15 BRAF mutation has indolent behavior: a single-institution experience. J. Clin. Endocrinol. Metab. 101(11), 4413–4420 (2016)PubMedCrossRef
5.
H. Guan, Y. Guo, L. Liu, R. Ye, W. Liang, H. Li et al. INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression. Cell Biosci. 8, 26 (2018)PubMedPubMedCentralCrossRef
6.
S. El-Sitt, B.D. Khalil, S. Hanna, M. El-Sabban, N. Fakhreddine, M. El-Sibai, DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma. Oncol. Rep. 28(2), 511–8 (2012)PubMedCrossRef
7.
Y. Ching, C.M. Wong, S.F. Chan, T.H. Leung, D.C. Ng, D.Y. Jin et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J. Biol. Chem. 278(12), 10824–30 (2003)PubMedCrossRef
8.
V. Ullmannova, N.C. Popescu, Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int. J. Oncol. 29(5), 1127–32 (2006)PubMed
9.
T.H. Leung, Y. Ching, J.W. Yam, C.M. Wong, T.O. Yau, D.Y. Jin et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc. Natl Acad. Sci. USA 102(42), 15207–12 (2005)PubMedPubMedCentralCrossRef
10.
T.H. Leung, J.W. Yam, L.K. Chan, Y.P. Ching, I.O. Ng, Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway. Liver Int. 30(9), 1315–23 (2010)PubMedCrossRef
11.
F. Gao, X. Yu, R. Meng, J. Wang, L. Jia, STARD13 is positively correlated with good prognosis and enhances 5-FU sensitivity via suppressing cancer stemness in hepatocellular carcinoma cells. Onco Targets Ther. 11, 5371–5381 (2018)PubMedPubMedCentralCrossRef
12.
F. Tang, R. Zhang, Y. He, M. Zou, L. Guo, T. Xi, MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One 7(5), e35435 (2012)PubMedPubMedCentralCrossRef
13.
S. Chang, S. He, G. Qiu, J. Lu, J. Wang, J. Liu et al. MicroRNA-125b promotes invasion and metastasis of gastric cancer by targeting STARD13 and NEU1. Tumour Biol. 37(9), 12141–12151 (2016)PubMedCrossRef
14.
M. Wu, X. Tan, P. Liu, Y. Yang, Y. Huang, X. Liu et al. Role of exosomal microRNA-125b-5p in conferring the metastatic phenotype among pancreatic cancer cells with different potential of metastasis. Life Sci. 255, 117857 (2020)PubMedCrossRef
15.
Y. Lu, W. Zheng, X. Rao, Y. Du, J. Xue, MicroRNA-9-5p facilitates lung adenocarcinoma cell malignant progression via targeting STARD13. Biochem. Genet. 60(6), 1865–1880 (2022)PubMedCrossRef
16.
L. Chen, W. Hu, G. Li, Y. Guo, Z. Wan, J. Yu, Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. Cell Mol. Biol. Lett. 24, 20 (2019)PubMedPubMedCentralCrossRef
17.
18.
Y. Qian, Y. Zhang, H. Ji, Y. Shen, L. Zheng, S. Cheng et al. LINC01089 suppresses lung adenocarcinoma cell proliferation and migration via miR-301b-3p/STARD13 axis. BMC Pulm. Med. 21(1), 242 (2021)PubMedPubMedCentralCrossRef
19.
J. Cai, J. Zhao, N. Zhang, X. Xu, R. Li, Y. Yi et al. MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma. J. Biol. Chem. 290(41), 24678–88 (2015)PubMedPubMedCentralCrossRef
20.
W. Liang, H. Guan, X. He, W. Ke, L. Xu, L. Liu et al. Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2. Oncotarget 6(31), 31780–91 (2015)PubMedPubMedCentralCrossRef
21.
A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102(43), 15545–50 (2005)PubMedPubMedCentralCrossRef
22.
W. He, Y. Sun, J. Ge, X. Wang, B. Lin, S. Yu et al. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma. Front Endocrinol. (Lausanne) 14, 1076640 (2023)PubMedCrossRef
23.
N. Cancer Genome Atlas Research, Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3), 676–90 (2014)CrossRef
24.
M. Xing, A.S. Alzahrani, K.A. Carson, Y.K. Shong, T.Y. Kim, D. Viola et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J. Clin. Oncol. 33(1), 42–50 (2015)PubMedCrossRef
25.
W. Pu, X. Shi, P. Yu, M. Zhang, Z. Liu, L. Tan et al. Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat. Commun. 12(1), 6058 (2021)PubMedPubMedCentralCrossRef
26.
H. Tang, L. Jiang, C. Zhu, R. Liu, Y. Wu, Q. Yan et al. Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Oncogene 38(17), 3119–3133 (2019)PubMedCrossRef
27.
Z. Miao, Q. Cao, R. Liao, X. Chen, X. Li, L. Bai et al. Elevated transcription and glycosylation of B3GNT5 promotes breast cancer aggressiveness. J. Exp. Clin. Cancer Res. 41(1), 169 (2022)PubMedPubMedCentralCrossRef
28.
D.S. Chandrashekar, S.K. Karthikeyan, P.K. Korla, H. Patel, A.R. Shovon, M. Athar et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25, 18–27 (2022)PubMedPubMedCentralCrossRef
29.
L. Jaafar, I. Fakhoury, S. Saab, L. El-Hajjar, W. Abou-Kheir, M. El-Sibai, StarD13 differentially regulates migration and invasion in prostate cancer cells. Hum. Cell 34(2), 607–623 (2021)PubMedCrossRef
30.
L. Sun, J. Sun, J.D. Song, High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC. Mol. Med. Rep. 19(6), 4881–4889 (2019)PubMedPubMedCentral
31.
S. Hanna, B. Khalil, A. Nasrallah, B.A. Saykali, R. Sobh, S. Nasser et al. StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion. Int J. Oncol. 44(5), 1499–511 (2014)PubMedPubMedCentralCrossRef
32.
A. Nasrallah, B. Saykali, S. Al Dimassi, N. Khoury, S. Hanna, M. El-Sibai, Effect of StarD13 on colorectal cancer proliferation, motility and invasion. Oncol. Rep. 31(1), 505–15 (2014)PubMedCrossRef
33.
Z. Huang, Z. Zhang, C. Zhou, L. Liu, C. Huang, Epithelial-mesenchymal transition: the history, regulatory mechanism, and cancer therapeutic opportunities. MedComm (2020). 3(2), e144 (2022)PubMedPubMedCentral
34.
L. Jaafar, Z. Chamseddine, M. El-Sibai, StarD13: a potential star target for tumor therapeutics. Hum. Cell 33(3), 437–443 (2020)PubMedCrossRef
35.
M. Al Haddad, R. El-Rif, S. Hanna, L. Jaafar, R. Dennaoui, S. Abdellatef et al. Differential regulation of rho GTPases during lung adenocarcinoma migration and invasion reveals a novel role of the tumor suppressor StarD13 in invadopodia regulation. Cell Commun. Signal 18(1), 144 (2020)PubMedPubMedCentralCrossRef
36.
Z. Yang, H. Chen, M. Shu, Y. Zhang, L. Xue, Y. Lin, DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway. Oncol. Lett. 17(2), 2107–2116 (2019)PubMed
37.
A.C. Braun, M.A. Olayioye, Rho regulation: DLC proteins in space and time. Cell Signal 27(8), 1643–51 (2015)PubMedCrossRef
38.
39.
40.
J. Chen, C. Jiang, L. Fu, C.L. Zhu, Y.Q. Xiang, L.X. Jiang et al. CHL1 suppresses tumor growth and metastasis in nasopharyngeal carcinoma by repressing PI3K/AKT signaling pathway via interaction with Integrin beta1 and Merlin. Int J. Biol. Sci. 15(9), 1802–1815 (2019)PubMedPubMedCentralCrossRef
41.
B.D. Khalil, S. Hanna, B.A. Saykali, S. El-Sitt, A. Nasrallah, D. Marston et al. The regulation of RhoA at focal adhesions by StarD13 is important for astrocytoma cell motility. Exp. Cell Res. 321(2), 109–22 (2014)PubMedCrossRef
42.
S. Abdellatef, I. Fakhoury, M.A. Haddad, L. Jaafar, H. Maalouf, S. Hanna et al. StarD13 negatively regulates invadopodia formation and invasion in high-grade serous (HGS) ovarian adenocarcinoma cells by inhibiting Cdc42. Eur. J. Cell Biol. 101(1), 151197 (2022)PubMedCrossRef
43.
44.
X. Li, L. Zheng, F. Zhang, J. Hu, J. Chou, Y. Liu et al. STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget 7(17), 23197–211 (2016)PubMedPubMedCentralCrossRef
45.
J. Hu, X. Li, X. Guo, Q. Guo, C. Xiang, Z. Zhang et al. The CCR2 3’UTR functions as a competing endogenous RNA to inhibit breast cancer metastasis. J. Cell Sci. 130(19), 3399–3413 (2017)PubMed
46.
L. Zheng, C. Xiang, X. Li, Q. Guo, L. Gao, H. Ni et al. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. J. Hematol. Oncol. 11(1), 72 (2018)PubMedPubMedCentralCrossRef
Metadata
Title
Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma
Authors
Chuimian Zeng
Hai Li
Weiwei Liang
Junxin Chen
Yilin Zhang
Hanrong Zhang
Haipeng Xiao
Yanbing Li
Hongyu Guan
Publication date
04-08-2023
Publisher
Springer US
Keyword
Metastasis
Published in
Endocrine / Issue 1/2024
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03468-7

Other articles of this Issue 1/2024

Endocrine 1/2024 Go to the issue

Original Article

Dynamic nomogram for predicting hungry bone syndrome before parathyroidectomy

Viewpoint

Measuring serum calcitonin in patients with thyroid nodules

Review

Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature

Original Article

The unique role of bone marrow adipose tissue in ovariectomy-induced bone loss in mice

Original Article

Practical recommendations for antihypertensive therapy during the primary aldosteronism screening test

Original Article

Screening for primary aldosteronism on and off interfering medications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits